Improving medication compliance in patients with depression: Use of orodispersible tablets

Advances in Therapy

Volumn 27, Issue 11, 2010, Pages 785-795

  Navarro, Victor ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Compliance; Major depressive disorder; Swallowing difficulties

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ARIPIPRAZOLE; CARBIDOPA PLUS LEVODOPA; CLONAZEPAM; CLOZAPINE; DIAZEPAM; DONEPEZIL; ESCITALOPRAM; KETOPROFEN; LAMOTRIGINE; LANSOPRAZOLE; MIRTAZAPINE; OLANZAPINE; OXAZEPAM; PERPHENAZINE; PIROXICAM; RISPERIDONE; SELEGILINE; SERTRALINE; SUMATRIPTAN; VALPROIC ACID; VENLAFAXINE; VOGLIBOSE; ZOLMITRIPTAN;

ALZHEIMER DISEASE; ANXIETY DISORDER; BIPOLAR DISORDER; DEPRESSION; DIABETES MELLITUS; DISPERSIBLE TABLET; DOCTOR PATIENT RELATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INDICATION; DRUG RELEASE; DYSPHAGIA; GASTROESOPHAGEAL REFLUX; HEALTH BEHAVIOR; HUMAN; MAJOR DEPRESSION; MIGRAINE; ORODISPERSIBLE TABLET; PARKINSON DISEASE; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; SCHIZOPHRENIA; SOCIAL ASPECT; SWALLOWING;

EID: 78649331259     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-010-0073-y     Document Type: Review

References (55)

1. Karasu TB, Gelenberg A, Merriam A, Wang P; American Psychiatric Association Steering Committee. Practice guideline for the treatment of patients with major depressive disorder. Second Edition. Available at: www.psychiatryonline.com/pracGuide/loadGuidelinePdf.aspx?file= MDD2e-Inactivated-04-16-09. Accessed February 1, 2010.
2. I.E. Babiker 1986 Noncompliance in schizophrenia Psychiatr Dev. 4 329 337 1:STN:280:DyaL2s3gsVSrsA%3D%3D 2883650
3. J.P. Lacro L.B. Dunn C.R. Dolder S.G. Leckband D.V. Jeste 2002 Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature J Clin Psychiatry 63 892 909 12416599
4. M. Olfson D. Mechanic S. Hansell C.A. Boyer J. Walkup P.J. Weiden 2000 Predicting medication noncompliance after hospital discharge among patients with schizophrenia Psychiatr Serv. 51 216 222 1:STN:280:DC%2BD3c7itFSjtg%3D%3D 10.1176/appi.ps.51.2.216 10655006 (Pubitemid 30082525)
5. M.R. DiMatteo H.S. Lepper T.W. Croghan 2000 Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence Arch Intern Med. 160 2101 2107 1:STN:280:DC%2BD3czptVKgug%3D%3D 10.1001/archinte.160.14.2101 10904452
6. N. Sawada H. Uchida T. Suzuki 2009 Persistence and compliance to antidepressant treatment in patients with depression: A chart review BMC Psychiatry 9 38 10.1186/1471-244X-9-38 19531229
7. A. Akincigil J.R. Bowblis C. Levin J.T. Walkup S. Jan S. Crystal 2007 Adherence to antidepressant treatment among privately insured patients with depression Med Care 45 363 369 10.1097/01.mlr.0000254574.23418.f6 17496721
8. C.R. Cantrell M.T. Eaddy M.B. Shah T.S. Regan M.C. Sokol 2006 Methods for evaluating patient adherence to antidepressant therapy: A real-world comparison of adherence and economic outcomes Med Care 44 300 303 10.1097/01.mlr. 0000204287.82701.9b 16565629 (Pubitemid 43755432)
9. T.K. Melartin H.J. Rytsälä U.S. Leskelä P.S. Lestelä-Mielonen T.P. Sokero E.T. Isometsä 2005 Continuity is the main challenge in treating major depressive disorder in psychiatric care J Clin Psychiatry 66 220 227 10.4088/JCP.v66n0210 15705008
10. W.E. Meijer M.L. Bouvy E.R. Heerdink J. Urquhart H.G. Leufkens 2001 Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors Br J Psychiatry 179 519 522 1:STN:280: DC%2BD38%2FgtVOltw%3D%3D 10.1192/bjp.179.6.519 11731355 (Pubitemid 34031677)
11. K. Demyttenaere A. Adelin P. Mesters W. Dewé K. De Bruyckere 2008 Six-month compliance with antidepressant medication in the treatment of major depressive disorder Int Clin Psychopharmacol. 23 36 42 10.1097/YIC. 0b013e3282f1c1d8 18090506 (Pubitemid 350294868)
12. E.H. Lin M. Von Korff W. Katon 1995 The role of the primary care physician in patients' adherence to antidepressant therapy Med Care 33 67 74 1:STN:280:DyaK2M7itl2qug%3D%3D 10.1097/00005650-199501000-00006 7823648
13. A. Wade J. Häring 2010 A review of the costs associated with depression and treatment noncompliance: The potential benefits of online support Int Clin Psychopharmacol. 25 288 296 10.1097/YIC.0b013e328339fbcf 20715299
14. J. Jin G.E. Sklar V.M.S. Oh S.C. Li 2008 Factors affecting therapeutic compliance: A review from the patient's perspective Ther Clin Risk Manag. 4 269 286 18728716
15. K.A. Hommel R.N. Baldassano 2010 Brief report: Barriers to treatment adherence in pediatric inflammatory bowel disease J Pediatr Psychol. 35 1005 1010 10.1093/jpepsy/jsp126 20026567
16. J. Lynch T. Kendrick M. Moore O. Johnston P.W.F. Smith 2006 Patients' beliefs about depression and how they relate to duration of antidepressant treatment. Use of a US measurement in a UK primary care population Primary Care Mental Health 4 207 217
17. J.A. Sirey M.L. Bruce G.S. Alexopoulos D.A. Perlick S.J. Friedman B.S. Meyers 2001 Perceived stigma and patient-rated severity of illness as predictors of antidepressant drug adherence Psychiatr Serv. 52 1615 1620 1:STN:280:DC%2BD3MnotVygsQ%3D%3D 10.1176/appi.ps.52.12.1615 11726752 (Pubitemid 33104454)
18. Society for the Advancement of Education. Swallowing difficulties cause for concern. USA Today. 2004 Oct. Available at: http://findarticles.com/p/ articles/mi-m1272/is-2713-133/ai-n6237884/. Accessed March 12, 2010.
19. H. Erlund J. Martikainen H. Turakka S. Kivelä A. Nissinen 1990 Problems with drug use among elderly men J Geriatr Drug Ther. 4 81 94
20. McCulloch TM, Jaffe D. Head and neck disorders affecting swallowing. GI Motility online; 2006. Available at: http://www.nature.com/gimo/contents/pt1/ full/gimo36.html Accessed August 11, 2010.
21. J.S. Gilbody 1991 Errors of deglutition - real and imagined; or, don't forget the psyche J Laryngol Otol. 105 807 811 1:STN:280:DyaK38%2FptF2nsA%3D%3D 10.1017/S0022215100117414 1753188
22. O. Bretan M.A. Henry F. [. Kerr-Corrêa 1996 Dysphagia and emotional distress Arq Gastroenterol. 33 60 65 1:STN:280:DyaK2s3msVSqug%3D%3D 9109970
23. A.B. Overgaard J. Hojsted R. Hansen J. Moller-Sonnergaard L.L. Christup 2001 Patients' evaluation of shape, size and colour of solid dosage forms Pharm World Sci. 23 185 188 1:STN:280:DC%2BD3Mnns1agsw%3D%3D 10.1023/A:1012050931018 11721676 (Pubitemid 33027102)
24. D. Wright 2002 Medication administration in nursing homes Nurs Stand. 16 33 38 12216309
25. J. Regan R. Sowman I. Walsh 2006 Prevalence of dysphagia in acute and community mental health settings Dysphagia 21 95 101 1:STN:280: DC%2BD28vntFSqug%3D%3D 10.1007/s00455-006-9016-9 16763936 (Pubitemid 44078541)
26. G.C. Manzoni P. Torelli 2007 The patient-physician relationship in the approach to therapeutic management Neurol Sci. 28 suppl.2 S130 S133 10.1007/s10072-007-0765-5 17508159 (Pubitemid 46813641)
27. Y. Fu Y. Schicheng S.H. Jeong S. Kimura K. Park 2004 Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies Crit Rev Ther Drug Carrier Syst. 21 433 475 1:CAS:528: DC%2BD2MXltlWgsbs%3D 10.1615/CritRevTherDrugCarrierSyst.v21.i6.10 15658933 (Pubitemid 41647575)
28. S.B. Shirsand S. Suresh O.V. Swamy 2009 Formulation design and optimization of fast dissolving clonazepam tablets Indian J Pharm Sci. 71 567 572 1:STN:280:DC%2BC3czmsVeqsA%3D%3D 10.4103/0250-474X.58189 20502581
29. I.S. Ahmed F.A. Fatahalla 2007 Pilot study of relative bioavailability of two oral formulations of ketoprofen 25 mg in healthy subjects. A fast-dissolving lyophilized tablet as compared to immediate release tablet Drug Dev Ind Pharm. 33 505 511 1:CAS:528:DC%2BD2sXlsFChsrY%3D 10.1080/ 03639040601150237 17520441 (Pubitemid 46808770)
30. C. Rasetti-Escargueil V. Grangé 2005 Pharmacokinetic profiles of two tablet formulations of piroxicam Int J Pharm. 296 129 134 10.1016/j.ijpharm.2005.02.006 (Pubitemid 40558796)
31. G. Carnaby-Mann M. Crary 2005 Pill swallowing by adults with dysphagia Arch Otolaryngol Head Neck Surg. 131 970 975 10.1001/archotol.131.11.970 16301368 (Pubitemid 41696391)
32. L. Solyom D. Sookman 1980 Fear of choking and its treatment. A behavioural approach Can J Psychiatry 25 30 34 1:STN:280:DyaL3c7ns1OjtA%3D%3D 6102887
33. S. Scemes R.C. Wielenska M.A. Savoia M. Bernik 2009 Choking phobia: Full remission following behavior therapy Rev Bras Psiquiatr. 31 257 260 10.1590/S1516-44462009005000002 19787155
34. M. Bhosle J.S. Benner M. DeKoven J. Shelton 2009 Difficult to swallow: Patient preferences for alternative valproate pharmaceutical formulations Patient Prefer Adherence 3 161 171 10.2147/PPA.S5691 19936158
35. H.C. Diener A. Gendolla 2005 Part IV: Effects of zolmitriptan orally disintegrating tablet on migraine symptoms and ability to perform normal activities: A postmarketing surveillance study in Germany Curr Med Res Opin. 21 suppl.3 S18 24 1:CAS:528:DC%2BD2MXhtFKktbzO 10.1185/030079905X46296 16083520 (Pubitemid 41152959)
36. A.J. Dowson B.R. Charlesworth 2003 Patients with migraine prefer zolmitriptan orally disintegrating tablet to sumatriptan conventional oral tablet Int J Clin Pract. 57 573 576 1:CAS:528:DC%2BD3sXotl2jsb4%3D 14529055
37. C.M. de Argila J. Ponce E. Márquez 2007 Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease: ACCEPTO study Clin Drug Investig. 27 765 770 10.2165/00044011-200727110-00003 17914895
38. J. Karagianis L. Grossman J. Landry 2009 A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS study Schizophr Res. 113 41 48 1:STN:280:DC%2BD1MvotFSjtw%3D%3D 10.1016/j.schres.2009.05.024 19535229
39. N. Koh S. Sakamoto F. Chino 2008 Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet Tohoku J Exp Med. 216 249 257 10.1620/tjem.216.249 18987459
40. E. Márquez-Contreras V. Gil J. López 2008 Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care Curr Med Res Opin. 24 569 576 10.1185/030079908X261104 18194594 (Pubitemid 351294405)
41. L. San M. Csillas A. Ciudad I. Gilaberte 2008 Olanzapine orally disintegrating tablet: A review of efficacy and compliance CNS Neurosci Ther. 14 203 214 1:CAS:528:DC%2BD1cXhtFentLvK 10.1111/j.1755-5949.2008.00053.x 18801113
42. A.R. Reig J.P. Fernández J.G. Cervera J.H. Navarro M.A. Ferragud E.G. Hortal 2006 Acceptance survey of a fast dissolving tablet pharmaceutical formulation in allergic patients. Satisfaction and expectancies Allergol Immunopathol. 34 107 112 10.1157/13088176 (Pubitemid 43967259)
43. H. Lieu-Seifert J. Houston D. Adams B.J. Kinon 2007 Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia J Clin Psychopharmacol. 27 392 394 10.1097/01.jcp.0000264986.32733.df (Pubitemid 47075511)
44. G. Uko-Ekpenyong 2006 Improving medication adherence with orally disintegrating tablets Nursing 36 20 21 16951598
45. F.L. Tornatore 2005 Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia J Clin Psychiatry 66 1493 1494 10.4088/JCP.v66n1121e 16420093
46. C. Normann M. Schmauss N. Bakri M. Gerwe A. Schreiner 2006 Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets Pharmacopsychiatry 39 209 212 1:CAS:528:DC%2BD2sXhs1yqtr0%3D 10.1055/s-2006-950498 17124642 (Pubitemid 44899721)
47. J.C. Nelson S.B. Hollander J. Betzel P. f. t. Smolen Mirtazapine Nursing Home Study Group 2006 Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older Int J Geriatr Psychiatry 21 898 901 10.1002/gps.1589 16955423 (Pubitemid 44492564)
48. S.P. Roose J.C. Nelson C. Salzman S.B. Hollander H. f. t. Rodrigues Mirtazapine in the Nursing Home Study Group 2003 Open-label study of mirtazapine orally disintegrating tablets in depressed patients in the nursing home Curr Med Res Opin. 19 737 746 10.1185/030079903125002441 14687445 (Pubitemid 37466144)
49. K. Behnke J. Søgaard S. Martin 2003 Mirtazapine orally disintegrating tablet versus sertraline: A prospective onset of action study J Clin Psychopharmacol. 23 358 364 1:CAS:528:DC%2BD3sXmt1Ohtr8%3D 10.1097/01.jcp.0000085408.08426.05 12920411 (Pubitemid 36951177)
50. O. Benkert A. Szegedi M. Philipp 2006 Mirtazapine orally disintegrating tablets versus venlafaxine extended release: A double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder J Clin Psychopharmacol. 26 75 78 1:CAS:528:DC%2BD28XhsFGhtr0%3D 10.1097/01.jcp.0000194622.99986.d6 16415711 (Pubitemid 43167095)
51. A. Delini-Stula H. van Oers A. van Willigenburg B. Oddens A.-J. Schutte E. van der Meulen 2009 Treating depression with different galenical drug formulations: Does it make a difference? The comparison of mirtazapine fast dissolving formulation (FDT) with conventional mirtazapine tablets (CT) Int J Psychiatry Clin Pract. 13 109 116 1:CAS:528:DC%2BD1MXlslChsb0%3D 10.1080/13651500802485262
52. A. Delini-Stula R. Bischof 2006 The results of the Swiss observational study of the new, fast-dissolving mirtazapine formulation in depressed patients Int J Psychiatry Clin Pract. 10 124 130 1:CAS:528:DC%2BD28XmvV2jsLk%3D 10.1080/13651500600579175 (Pubitemid 43879977)
53. V. Danileviciūte V. Adomaitiene A. Sveikata R. Maciulaitis E. Kadusevicius V. [. Volbekas 2006 Compliance in psychiatry: Results of a survey of depressed patients using orally disintegrating tablet Medicina (Kaunas) 42 1006 1012
54. Preskorn SH, Ross R, Stanga CY. Selective serotonin reuptake inhibitors. In: Preskorn SH, Feighner HP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Berlin: Springer; 2004; 241-262.
55. A. Cipriani T.A. Furukawa G. Salanti 2009 Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple treatment meta-analysis Lancet 373 746 758 1:CAS:528:DC%2BD1MXisVOrtr8%3D 10.1016/S0140-6736(09)60046-5 19185342